<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624699</url>
  </required_header>
  <id_info>
    <org_study_id>GLK-iStent-inject</org_study_id>
    <nct_id>NCT03624699</nct_id>
  </id_info>
  <brief_title>Investigation of the iStent Inject® Devices in Open-Angle Glaucoma</brief_title>
  <official_title>A Prospective, Unmasked, Single-Site Investigation of the iStent Inject® Devices Implanted in Combination With Cataract Surgery in Patients With Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>dr. Kaweh Mansouri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Vision Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and intraocular pressure (IOP) lowering
      effect of two iStent inject devices in combination with cataract surgery in patients with
      mild-to-moderate open-angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering from open-angle glaucoma who are planning to undergo cataract surgery and
      are matching the inclusion criteria will be offered to join the study until the desired
      sample size (50) is reached. Combined cataract-iStent surgery will be performed as per the
      devices' manufacturers' instructions. Two iStent inject devices will be micro-invasively
      implanted in the trabecular meshwork of the eye during planned cataract surgery. Six
      post-operative follow-ups will be carried out over a duration of 12 months, during which
      various measurements will be made. Performance Outcomes will analyse the proportion of
      patients with IOP reduction of ≥ 20% vs. baseline mean IOP, at 6 and 12 months. Quality of
      life outcome will look at the improvement in perceived quality of life as expressed in the
      NEI VFQ-25 questionnaires from baseline to 3 and 12 months. The rate of adverse events will
      be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Historic control (before vs. after intervention).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Outcome: IOP reduction</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with IOP reduction of ≥ 20% vs. baseline mean IOP, at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life: NEI VFQ-25 score</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in perceived quality of life as expressed in the NEI VFQ-25 (National Eye Institute Vision Function) questionnaires from baseline to 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome: Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of adverse events through the follow-up period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Glaukos iStent inject®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glaukos iStent inject®</intervention_name>
    <description>iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma</description>
    <arm_group_label>Glaukos iStent inject®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma

          -  Mild to moderate glaucoma (defined as C/D ratio ≤ 0.8)

          -  Phakic eye requiring cataract surgery

          -  Preoperative IOP up to 30 mmHg (medicated or not)

          -  Patients with side-effects to, or complications from, medications

          -  Patients who would benefit from a reduction of IOP and/or reduction of medication

          -  Normal angle anatomy as determined by gonioscopy;

          -  Absence of peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities
             that could impair proper placement of iStent inject device

          -  Able and willing to attend scheduled follow-up exams for 12 months postoperatively

          -  Able and willing to provide written informed consent on the approved Informed Consent
             Form

        Exclusion Criteria:

          -  Inclusion of the fellow eye in this study (only one eye per subject)

          -  Aphakic patients or pseudophakic patients

          -  Prior stent implantations in the study eye

          -  Eyes with primary angle closure glaucoma, or any secondary angle closure glaucoma

          -  Traumatic or uveitic glaucoma; or any glaucoma associated with vascular disorders

          -  Patients with any type of condition that may cause elevated episcleral venous pressure

          -  Functionally significant visual field loss, including severe nerve fiber bundle
             defects such as Bjerrum scotoma

          -  Prior glaucoma treatment (laser or surgery)

          -  Any active corneal inflammation, edema, or opacity severe-enough to impair gonioscopy
             / fundus examination

          -  Any pathology for which, in the investigator's judgment, the following would be either
             at risk or contraindicated:

               -  stent implantation,

               -  compliance to elements of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaweh Mansouri, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>Glaucoma Research Centre, Montchoisi Clinic, Lausanne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André Mermoud, MD</last_name>
    <role>Study Director</role>
    <affiliation>Glaucoma Research Centre, Montchoisi Clinic, Lausanne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaweh Mansouri, MD MPH</last_name>
    <phone>021 619 37 42</phone>
    <phone_ext>+41</phone_ext>
    <email>kmansouri@gsvn.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>André Mermoud, MD</last_name>
    <phone>021 619 37 42</phone>
    <phone_ext>+41</phone_ext>
    <email>amermoud@gsvn.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Glaucoma Research Centre, Montchoisi Clinic</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaweh Mansouri, MD MPH</last_name>
      <phone>021 619 37 42</phone>
      <phone_ext>+41</phone_ext>
      <email>kmansouri@gsvn.ch</email>
    </contact>
    <contact_backup>
      <last_name>André Mermoud, MD</last_name>
      <phone>021 619 37 42</phone>
      <phone_ext>+41</phone_ext>
      <email>amermoud@gsvn.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Kaweh Mansouri, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>André Mermoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Gillmann, MBBS MArch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Vision Network</investigator_affiliation>
    <investigator_full_name>dr. Kaweh Mansouri</investigator_full_name>
    <investigator_title>Sponsor-Investigator, Primary investigator</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>Minimally Invasive Glaucoma Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

